An international, multi-centre, prospective three arm parallel-group, phase II proof of concept study comparing the efficacy and safety of two dosage regimens (BID 7 days and TID 7 days) of TD1414 2% cream and one dosage regimen (BID 7 days) of Bactroban® (mupirocin) 2% cream in adults and children down to 2 years of age with impetigo or SITL. (drugpatentwatch.com)
Pediatric patients the pharmacokinetic properties of mupirocin following intranasal application of bactroban nasal ointment have not been adequately characterized in neonates or other children younger than 12 years, and in addition, the safety and efficacy of the product in children younger than 12 years have not been established. (larumbejoyeros.com)
Mupirocin (Bactroban) ointment is prescribed for the treatment of bacterial skin infections such as impetigo, cellulitis and folliculitis. (militarywifenetwork.com)
In the US, Customers can order Bactroban Ointment online , or as the generic alternative, Mupirocin as well as many more quality medications from PrescriptionPoint. (militarywifenetwork.com)
Mupirocin Ointment USP, 2% is available as follows:22 gram tube (NDC 45802-112-22)Store at 20-25C (68-77F) [see USP Controlled Room Temperature].Bactroban Nasal(R) is registered trademark of GlaxoSmithKline.MADE IN ISRAELMANUFACTURED BY PERRIGO, YERUHAM 80500, ISRAELRepacked by: H.J. Harkins Company, Inc.Nipomo, CA 93444Rev: 11/11. (drugcentral.org)
Ointment USP7
Each gram of Mupirocin Ointment USP, 2% contains 20 mg mupirocin in a bland water miscible ointment base (polyethylene glycol ointment, N.F.) consisting of polyethylene glycol 400 and polyethylene glycol 3350. (nih.gov)
Mupirocin Ointment USP, 2% is not for ophthalmic use. (nih.gov)
If a reaction suggesting sensitivity or chemical irritation should occur with the use of Mupirocin Ointment USP, 2%, treatment should be discontinued and appropriate alternative therapy for the infection instituted. (nih.gov)
Mupirocin Ointment USP, 2% is not formulated for use on mucosal surfaces. (nih.gov)
small amount of Mupirocin Ointment USP, 2% should be applied to the affected area times daily. (drugcentral.org)
The effect of the concurrent application of Mupirocin Ointment USP, 2% and other drug products has not been studied. (drugcentral.org)
Nasal ointments or sprays and oral antibiotics have variable efficacy, and their use frequently results in antimicrobial resistance among S aureus strains. (johnshopkins.edu)
Of the commonly used agents, mupirocin (pseudomonic acid) ointment has been shown to be 97% effective in reducing S aureus nasal carriage. (johnshopkins.edu)
4% of S aureus nasal carriers who received mupirocin acquired S aureus health care-related infections compared with 7.7% of S aureus nasal carriers who received placebo (P = .02). (johnshopkins.edu)
Aureus4
The S aureus surgical-site infection rate was not reduced significantly, but carriers who received mupirocin before cardiothoracic or general surgery operations had almost 50% fewer S aureus surgical-site infections than carriers who received placebo. (johnshopkins.edu)
Mupirocin has been shown to be active against most strains of Staphylococcus aureus and Streptococcus pyogenes, both in vitro and in clinical studies. (nih.gov)
Mupirocin ointment or povidone-iodine applied to the nares prior to surgery may be equally effective in short term Staphylococcus aureus decolonization. (jortho.org)
High-level plasmid-mediated resistance (MIC 1024 mcg/mL) has been reported in some strains of S. aureus and coagulase-negative staphylococci.Mupirocin is bactericidal at concentrations achieved by topical administration. (drugcentral.org)
Systemic absorption1
Application of 14 C-labeled mupirocin ointment to the lower arm of normal male subjects followed by occlusion for 24 hours showed no measurable systemic absorption (less than 1.1 nanogram mupirocin per milliliter of whole blood). (nih.gov)
Strains2
Mupirocin is active against most strains of Staphylococcus epidermidis and Staphylococcus saprophyticus. (nih.gov)
However, most CA-MRSA strains are or readily become resistant to mupirocin. (medscape.com)
Vitro1
Due to this unique mode of action, mupirocin demonstrates no in vitro cross-resistance with other classes of antimicrobial agents. (nih.gov)
Infections1
Impetigo and other minor skin infections (ie, superficial or localized infections) may be treated with a topical agent such as mupirocin or retapamulin. (medscape.com)
Bacterial1
Mupirocin inhibits bacterial protein synthesis by reversibly and specifically binding to bacterial isoleucyl transfer-RNA synthetase. (nih.gov)
Topical administration1
Mupirocin is bactericidal at concentrations achieved by topical administration. (nih.gov)
Elimination1
In a study conducted in seven healthy adult male subjects, the elimination half-life after intravenous administration of mupirocin was 20 to 40 minutes for mupirocin and 30 to 80 minutes for monic acid. (nih.gov)
Evaluate1
The purpose of this study is to evaluate the safety and efficacy of a 28-day course of vancomycin for inhalation, 250 mg twice a day, (in combination with oral antibiotics) in eliminating MRSA from the respiratory tract of individuals with CF and persistent MRSA infection. (drugpatentwatch.com)
Application1
Measurable radioactivity was present in the stratum corneum of these subjects 72 hours after application.Following intravenous or oral administration, mupirocin is rapidly metabolized. (drugcentral.org)
Oral2
Following intravenous or oral adminstration, mupirocin is rapidly metabolized. (nih.gov)
Some authors have demonstrated efficacy with 1 week of parenteral therapy followed with 3 weeks of oral therapy. (medscape.com)
Therapy2
Joint fluid that reaccumulates should be removed, and a sample should be cultured to assess the efficacy of therapy and to make the patient more comfortable. (medscape.com)
Y All equipment used in the delivery and monitoring of therapy should comply with the relevant Standards for medical electrical equipment (BS-EN 60601-2-16: 1998, BS5724-2-16:1998. (onlinepdfcatalog.com)
Effect1
97%), and the effect of wound secretions on the MICs of mupirocin has not been determined. (nih.gov)